Skip to content

MDMA research: what the evidence shows

(3,4-Methylenedioxymethamphetamine) An entactogen investigated primarily as an adjunct to psychotherapy for post-traumatic stress disorder.

State of the evidence

Synthesized

Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.

MDMA-assisted therapy shows consistent, large reductions in PTSD symptoms across randomized trials, including in severe, chronic, and treatment-resistant cases, with effects sustained up to 12 months in one dose-response trial and no serious drug-related adverse events reported. Separately, animal and human imaging work indicates MDMA can damage serotonin nerve terminals, and pharmacology studies show it releases serotonin, dopamine, and norepinephrine. The main caveats are small samples in most trials, limited long-term and non-PTSD population data, and uncertainty about how animal neurotoxicity doses translate to clinical or recreational human use.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 17 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 2021 RCT 90 Supports MDMA-assisted therapy produced significantly greater reductions in PTSD symptoms (d = 0.91) and functional impairment (d = 0.43) than placebo, with no serious adverse events.
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. 2010 RCT 20 Supports MDMA-assisted psychotherapy reduced PTSD symptom scores significantly more than placebo at all post-baseline time points, with 83% versus 25% clinical response and no drug-related serious adverse events.
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. 2018 RCT (dose-response, phase 2) 26 Supports Active MDMA doses (75 mg and 125 mg) with psychotherapy produced large PTSD symptom reductions versus a 30 mg control, and reductions persisted at 12 months after open-label dosing.
Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings 1998 PET imaging study Opposes PET imaging showed a decrease in a structural component of brain serotonin neurons in human MDMA users.
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity 1988 animal experiment Opposes Repeated MDMA (20 mg/kg twice daily for 4 days) caused selective ablation of serotonin axon terminals in rat forebrain while sparing catecholamine axons.
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. 1987 animal experiment Opposes Repeated MDMA (20 mg/kg twice daily for 4 days) produced long-lasting 50-75% reductions in serotonin uptake site density and 30-60% reductions in serotonin metabolite levels, without long-term catecholamine changes.
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. 1987 animal experiment Opposes MDMA caused a reversible acute serotonin depletion followed by a longer-lasting depletion with reduced serotonin uptake sites, specific to the (+)-stereoisomer and blocked by fluoxetine.
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. 1992 laboratory study Supports MDMA stimulates serotonin efflux via both plasma membrane and vesicular transporters through direct transporter interaction and pH gradient dissipation.
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs 2006 in vitro laboratory study Supports MDMA was more potent at the serotonin transporter than at the dopamine transporter, unlike amphetamine and methamphetamine.
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin 2000 experimental study Supports Among stimulants tested, norepinephrine release potency, not dopamine release potency, correlated with oral doses producing amphetamine-type subjective effects in humans.
Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor 2001 pharmacological characterization Supports MDMA and other amphetamines act as potent agonists at a rat trace amine receptor, suggesting an additional mechanism beyond transporter proteins.
Human Pharmacology of MDMA 2004 review Mixed MDMA releases and inhibits reuptake of serotonin, dopamine, and norepinephrine, producing entactogen effects and acute toxicity such as serotonin syndrome.
Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens 1986 theoretical Unclear Argues that MDMA and MBDB form a distinct therapeutic class, 'entactogens,' separate from classic hallucinogens and stimulants.
Subjective Reports of the Effects of MDMA in a Clinical Setting 1986 observational Supports MDMA produced predominantly positive subjective effects in a clinical setting, enhancing emotional openness and introspection with minimal adverse reactions.
Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug 1992 cross-sectional survey 100 Mixed Users reported positive mood and intimacy as main effects, with tolerance to positive effects and increasing negative effects with use.
Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 cross-sectional survey Unclear Describes self-reported health outcomes attributed to recent MDMA and other psychedelic use, but no specific outcomes or effect sizes are reported in the available text.
Neuromodulation, Ketamine, and MDMA in Borderline Personality Disorder 2026 commentary Unclear Argues that MDMA-assisted psychotherapy has not been studied in borderline personality disorder and that standard protocols would likely need significant modification.

Points of agreement

  • Randomized trials consistently show large PTSD symptom reductions with MDMA-assisted therapy versus placebo or low-dose control.
  • Trials report no serious drug-related adverse events in supervised clinical use.
  • Pharmacology studies agree MDMA acts primarily through serotonin transporters, with additional dopamine and norepinephrine effects.
  • Animal and human imaging studies agree MDMA can reduce markers of serotonin neuron integrity.

Conflicts

  • Clinical trials emphasize safety and tolerability under supervised conditions, while animal and imaging studies document serotonergic neurotoxicity.
  • Recreational users report tolerance and increasing negative effects with repeated use, contrasting with controlled single- or few-dose clinical protocols.

Gaps

  • Long-term durability beyond 12 months is largely unstudied.
  • Blinding integrity in psychedelic trials is uncertain.
  • Most trials are small and limited to PTSD; other populations such as borderline personality disorder are unstudied.
  • Dose-response and translation of animal neurotoxicity doses to human clinical or recreational use remain unclear.
  • Adverse outcome data from large representative surveys are not yet reported in detail.
Browse these studies in the library

Common questions

What does the research agree on about MDMA?
  • Randomized trials consistently show large PTSD symptom reductions with MDMA-assisted therapy versus placebo or low-dose control.
  • Trials report no serious drug-related adverse events in supervised clinical use.
  • Pharmacology studies agree MDMA acts primarily through serotonin transporters, with additional dopamine and norepinephrine effects.
  • Animal and human imaging studies agree MDMA can reduce markers of serotonin neuron integrity.
Where do studies on MDMA conflict?
  • Clinical trials emphasize safety and tolerability under supervised conditions, while animal and imaging studies document serotonergic neurotoxicity.
  • Recreational users report tolerance and increasing negative effects with repeated use, contrasting with controlled single- or few-dose clinical protocols.
What is still unknown about MDMA?
  • Long-term durability beyond 12 months is largely unstudied.
  • Blinding integrity in psychedelic trials is uncertain.
  • Most trials are small and limited to PTSD; other populations such as borderline personality disorder are unstudied.
  • Dose-response and translation of animal neurotoxicity doses to human clinical or recreational use remain unclear.
  • Adverse outcome data from large representative surveys are not yet reported in detail.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

3,446 articles · 641 from the last two years · 8,725,776 participants across 1,069 studies reporting sample size

Common study designs

review 603 experimental study 218 observational cohort 156 randomized controlled trial 114 theoretical or philosophical paper 256

MDMA research by condition and practice

Data updated

Studies whose primary subject is both MDMA and the condition or practice, with reviews counted by the study design extracted from each abstract. Registered trials are from ClinicalTrials.gov. This maps how much research exists, not how well anything works.

MDMA research by condition and practice: studies, meta-analyses and systematic reviews, registered clinical trials, the highest trial phase, and studies from the last two years. Most studies first.
Condition or practice Studies Meta-analyses and systematic reviews Registered trials Highest phase From the last two years
PTSD 202 studies 22 meta-analyses and systematic reviews 50 registered trials up to Phase 3 61 from the last two years
Psychedelic-assisted therapy 148 studies 19 meta-analyses and systematic reviews 21 registered trials up to Phase 3 47 from the last two years
Anxiety 94 studies 7 meta-analyses and systematic reviews 4 registered trials up to Phase 2 18 from the last two years
Addiction 80 studies 6 meta-analyses and systematic reviews 6 registered trials up to Phase 2/3 18 from the last two years
Depression 54 studies 6 meta-analyses and systematic reviews 1 registered trial No phase listed 19 from the last two years

Research volume by year

Compare topics →

2,057 studies whose primary subject is MDMA since 2002

Studies about MDMA per year, 2002 to 2026, peaking at 155 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 100 200 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA per year, 2002 to 2026, peaking at 155 in 2026
Year Studies
2002 41
2003 37
2004 55
2005 37
2006 73
2007 63
2008 81
2009 78
2010 99
2011 130
2012 60
2013 41
2014 78
2015 47
2016 73
2017 86
2018 92
2019 71
2020 66
2021 73
2022 122
2023 126
2024 134
2025 139
2026 155

Research

Synthesize the evidence → Search all →

From Acute MDMA Experiences to Lasting Change: Self-Compassion’s Role in MDMA-Assisted Psychotherapy for Social Anxiety Disorder

October 25, 2026 Christina Chwyl, Mary K. Lear, Sunjeev K. Kamboj et al. preprint

Objectives: Self-compassion may benefit individuals with social anxiety disorder and serve as a mechanism of change within 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT). Methods: In this secondary analysis of 20 adults with social anxiety disorder who underwent MDMA-AT for social anxiety disorder (NCT05138068), we examined whether both trait self-compassion changes across...

DOI: 10.31234/osf.io/3ard8_v1 (opens in new tab)

MDMA Safety Across Contexts: Pharmaceutical Trials and Real-World Ecstasy Compared Side by Side

Zenodo (CERN European Organization for Nuclear Research) October 24, 2026 Odin Loch preprint

Background. Safety is a property of a drug, in a population, in a context. Pharmaceutical MDMA (midomafetamine) given in a monitored psychotherapy trial, and material sold as ecstasy or MDMA outside that setting, are different exposures. This preprint compares those contexts side by side. It does not produce one pooled safety number. Methods. This is a rapid computational evidence synthesis:...

DOI: 10.5281/zenodo.23612322 (opens in new tab)

USO TERAPÊUTICO CONTROLADO DE MDMA NO TEPT: UMA REVISÃO INTEGRATIVA ENTRE 2010 E 2025

Brazilian Journal of Health Review October 21, 2026 Pablo Henrique Lacerda Estaffe da Silva, Samela Demore Correa, Érico Torrieri

O uso terapêutico controlado de MDMA (3,4-metilenodioximetanfetamina) associado à psicoterapia tem ganhado destaque como abordagem para o transtorno de estresse pós-traumático (TEPT), especialmente em casos resistentes às terapias convencionais. Objetivo: sintetizar as evidências publicadas entre 2010 e 2025 sobre a eficácia, a segurança e os mecanismos de ação da terapia assistida por MDMA no...

DOI: 10.34119/bjhrv9n5-127 (opens in new tab)

Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment

October 20, 2026 Christina Chwyl, Mary K. Lear, Jason B. Luoma preprint

By fostering certain self-transcendent experiences (STE)—those characterized by interconnectedness and other-oriented emotions—3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has been hypothesized to disrupt social anxiety disorder maintenance processes, including negative self-focus, self-criticism, and isolation, thereby enhancing wellbeing. This secondary analysis used...

DOI: 10.31234/osf.io/kbxdq_v1 (opens in new tab)

What goes up must comedown: prevalence rates, characteristics, and coping strategies concerning MDMA aftereffects.

Psychopharmacology October 17, 2026 Sean P. Goldy, Kelcy A Klein, David B. Yaden et al.

MDMA is increasingly being studied for therapeutic applications, yet the prevalence and characteristics of post-acute negative effects remain debated. We aimed to characterize MDMA's post-acute negative effects, including prevalence and symptom profile among recreational users. Given preclinical work and limited human evidence suggesting that certain supplements and antidepressants may mitigate...

DOI: 10.1007/s00213-026-07187-5 (opens in new tab) Full text (opens in new tab) MDMA Aftereffects Mood

Afebrile Convulsive Status Epilepticus Associated with Suspected Accidental 3,4-Methylenedioxymethamphetamine (MDMA) Intoxication in A 20-Month-Old Boy: A Case Report

Asian Journal of Pediatric Research October 8, 2026 Soukaina Bendouz, Hind Lachraf, Hanane Laji et al.

Aims: To report an unusual presentation of suspected accidental 3,4-methylenedioxymethamphetamine (MDMA) intoxication as afebrile convulsive status epilepticus (CSE) in a toddler and to emphasise the importance of considering toxicological causes when conventional investigations are unrevealing. Presentation of Case: A previously healthy 20-month-old boy presented with generalised afebrile CSE...

DOI: 10.9734/ajpr/2026/v16i11584 (opens in new tab)

Rapid chemical profiling of ecstasy tablets using portable near-infrared spectroscopy for forensic intelligence and early response applications.

Forensic Science International October 8, 2026 Marina Charest, Emilia Gianola, Lucas Jaquet et al.

Chemical profiling of illicit drugs has traditionally relied on laboratory-based techniques such as gas chromatography-mass spectrometry (GC-MS). Recent developments in portable drug testing devices have facilitated the decentralization of forensic capabilities, enabling field users to obtain rapid results. In this study, portable near-infrared (NIR) spectroscopy was evaluated for the chemical...

DOI: 10.1016/j.forsciint.2026.113156 (opens in new tab) Full text (opens in new tab) MDMA Gas chromatography Nir spectroscopy Harm reduction +3

Neuromodulación, ketamina y MDMA en el trastorno límite de la personalidad

September 29, 2026 Paul S. Links

Considere la neuromodulación para pacientes con TLP y depresión mayor comórbida que no hayan respondido a antidepresivos y otros medicamentos. La evidencia de revisiones sistemáticas respalda un papel complementario en estos casos. Al usar ketamina en el TLP, vigile cuidadosamente la aparición de conductas desinhibidas y el aumento de la ideación suicida. Los reportes de casos han documentado...

DOI: 10.64239/pi-es-vl11210 (opens in new tab)

Neuromodulation, kétamine et MDMA dans le trouble de la personnalité borderline

September 29, 2026 Paul S. Links

Envisagez la neuromodulation pour les patients atteints de trouble de la personnalité borderline présentant une dépression majeure comorbide et un échec des antidépresseurs et d'autres médicaments. Les données d'une revue systématique soutiennent un rôle complémentaire dans ces cas. Lors de l'utilisation de la kétamine dans le trouble de la personnalité borderline, surveillez attentivement les...

DOI: 10.64239/pi-fr-vl11210 (opens in new tab)

Neuromodulação, cetamina e MDMA no transtorno de personalidade borderline

September 29, 2026 Paul S. Links

Considere a neuromodulação para pacientes com TPB e depressão maior comórbida que não responderam a antidepressivos e outras medicações. Evidências de revisões sistemáticas apoiam um papel complementar nesses casos. Ao utilizar cetamina no TPB, monitore cuidadosamente comportamentos desinibidos e aumento da ideação suicida. Relatos de caso documentaram ambas as reações como efeitos negativos. A...

DOI: 10.64239/pi-pt-br-vl11210 (opens in new tab)

Clinical trials

All MDMA trials →